Rotigotine Transdermal Patch Does Not Make Parkinson Disease Patients Sleepy During Daytime.


OBJECTIVES:To assess quantitatively the influence of rotigotine transdermal patch on daytime sleepiness, the most common adverse event by non-ergot dopamine agonists (DAs), in Parkinson disease (PD) patients. METHODS:An open-label study enrolled PD patients with unsatisfactory control of motor symptoms. Treatment with rotigotine transdermal patch was titrated to optimal dose (4-8 mg/24 hours) over 2 to 4 weeks. Primary outcome was Epworth Sleepiness Scale (ESS) for daytime sleepiness. Secondary outcomes included Hoehn&Yahr stage, time spent with dyskinesia, Clinical Global Impression of Improvement (CGI-I) of motor symptoms, adverse events, and compliance. RESULTS:The subjects were 31 PD patients (age 72 ± 8, Hoehn &Yahr stage 2.7 ± 0.9, mean ± SD). The ESS did not increase after rotigotine treatment (7.2 ± 4.9 before treatment, 6.2 ± 4.0 with 4 mg/24 hour, and 8.1 ± 6.4 with 8 mg/24 hour). The CGI-I score improved after treatment; responder rate reached 88.9% with 8 mg/24 hours. No patients showed worsening in other secondary outcomes. In 13 patients treated with equivalent doses of rotigotine switched from other DAs (pramipexole, ropinirole, and cabergoline), ESS did not increase after treatment (10.0 ± 4.6 before and 8.6 ± 4.5 after treatment) and decreased without worsening of CGI-I in 54% patients. Other secondary outcomes did not worsen after treatment. CONCLUSIONS:Twenty four-hour transdermal delivery of rotigotine at doses up to 8 mg/24 hours does not worsen the daytime sleepiness in PD patients and often improves it when switched from other non-ergot DAs. This is achieved together with satisfactory improvement in motor symptoms, demonstrating that this new modality of non-ergot DA is well tolerated and beneficial in PD patients.


Clin Neuropharmacol


Ohta K,Osada T




Has Abstract


2015-11-01 00:00:00












  • A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder.

    abstract:OBJECTIVES:Autism spectrum disorders (ASDs) have core impairments in social communication as well as the presence of repetitive, stereotypic behaviors and restricted interests. Older adolescents and young adults are particularly impacted by these deficits. Preclinical data implicate glutamatergic dysfunction in the pat...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验


    authors: Urbano M,Okwara L,Manser P,Hartmann K,Herndon A,Deutsch SI

    更新日期:2014-05-01 00:00:00

  • The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease.

    abstract::Levodopa (LD) is one of the most effective drugs for clinical symptoms in patients with Parkinson disease (PD). Most PD patients are advanced in age and may have trouble with LD absorption because aging influences drug absorption processes. Previous reports have indicated that ascorbic acid (AsA) can reduce LD dosage ...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章


    authors: Nagayama H,Hamamoto M,Ueda M,Nito C,Yamaguchi H,Katayama Y

    更新日期:2004-11-01 00:00:00

  • Paroxetine-associated hypereosinophilia may clinically resemble a panic attack.

    abstract::Hypereosinophilia is asymptomatic but can induce organ damage, which may cause neurological system abnormalities. We recently encountered a 29-year-old woman with depressive episodes who had eosinophilia as well as hyperventilation attacks, tremor, insomnia, and arthralgia of extremities after receiving paroxetine tre...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章


    authors: Yasui-Furukori N,Sato Y,Kato H,Kaneko S

    更新日期:2012-01-01 00:00:00

  • Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three-times-daily dosage schedules.

    abstract::Data on a twice-daily dosage schedule with moclobemide in the treatment of depression is limited. In this study, moclobemide 150 mg twice daily (b.i.d.) was compared to two different three-times-daily (t.i.d.) regimens with total daily dosages of 300 and 450 mg, respectively, over a 6-week period. The study was random...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验


    authors: Gagiano CA,Hart GA,Bodemer W,Schall R

    更新日期:1994-01-01 00:00:00

  • Changes in Cognitive Processing Speed, Mood, and Fatigue in an Observational Study of Persons With Multiple Sclerosis Treated With Dalfampridine-ER.

    abstract:OBJECTIVE:Multiple sclerosis (MS) is a degenerative neurological condition that results in impairments in multiple domains including cognition, fatigue, and mood. Dalfampridine-extended release (D-ER) has been approved to improve walking in persons with MS. It is plausible that D-ER could improve cognition, fatigue, an...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章


    authors: Triche EW,Ruiz JA,Olson KM,Lo AC

    更新日期:2016-03-01 00:00:00

  • The Optimal Dose of Amobarbital in the Wada Test for the Presurgical Evaluation of Patients With Temporal Lobe Epilepsy.

    abstract:OBJECTIVE:The use of amobarbital in the Wada test varied between epilepsy centers, with no unified dosing or protocols available in the literature to standardize its use. We aimed to determine the dose of amobarbital in the presurgical evaluations of patients with temporal lobe epilepsy. METHODS:A retrospective study ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章


    authors: Bajammal S,Babtain F,Alqadi K,Baeesa S,Kurdi K,Madani N,Al Said Y

    更新日期:2020-11-01 00:00:00

  • Treatment of psychogenic polydipsia with acetazolamide: a report of 5 cases.

    abstract:OBJECTIVE:Psychogenic polydipsia occurs frequently in patients with chronic psychiatric illness and is often unmanageable. We herein report 5 patients in whom acetazolamide was trialed for this symptom. METHODS:We encountered a case in which polydipsia improved with incidental administration of acetazolamide. We then ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章


    authors: Takagi S,Watanabe Y,Imaoka T,Sakata M,Watanabe M

    更新日期:2011-01-01 00:00:00

  • One Plus One Sometimes Equals More Than Two: Long-acting Injectable Aripiprazole Adjunction in Clozapine-Resistant Schizophrenia.

    abstract::In this report, we present a patient whose positive symptoms did not improve despite being treated with clozapine monotherapy at a therapeutic dose for 4 months, and whose symptoms began to resolve after aripiprazole long-acting injection adjunction to clozapine. A 22-year-old man was diagnosed as having schizophrenia...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章


    authors: Balcioglu YH,Gokcay H,Yesilkaya UH

    更新日期:2020-09-01 00:00:00

  • The reversibility of "permanent" tardive dyskinesia.

    abstract::Neuroleptic-induced tardive dyskinesia (TD) that persists for 1 year or more following withdrawal of neuroleptics is usually said to be permanent. Early spontaneous remissions have been well described but most such remissions occurred within the first few months following neuroleptic withdrawal, and no published studi...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章


    authors: Klawans HL,Tanner CM,Barr A

    更新日期:1984-01-01 00:00:00

  • Serotonin Syndrome Following Combined Administration of Dopaminergic and Noradrenergic Agents in a Patient With Akinetic Mutism After Frontal Intracerebral Hemorrhage: A Case Report.

    abstract:BACKGROUND:Serotonin syndrome (SS) is a potentially life-threatening condition that can be caused by use of proserotonergic drugs. Several studies have reported that combined administration of various medications may induce SS. We report a case of SS in a patient who was being treated with dopaminergic and noradrenergi...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章


    authors: Jeon DG,Kim YW,Kim NY,Park JH

    更新日期:2017-07-01 00:00:00

  • Low-dose bromocriptine in the early phases of Parkinson's disease.

    abstract::The effect of bromocriptine at doses up to 20 mg/day was studied in a single-blind format with a placebo phase in 15 Parkinson's disease patients with mild-to-moderate disability who had not been previously treated with levodopa. For the 11 patients who completed the 9 month trial, both Northwestern University Disabil...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章


    authors: Tolosa E,Blesa R,Bayes A,Forcadell F

    更新日期:1987-04-01 00:00:00

  • Cytokine production in anorexia nervosa.

    abstract::The capacity of peripheral blood mononuclear cells (PBMCs) of anorexia nervosa (AN) patients to produce interleukin-1 (IL-1), interleukin-2 (IL-2), and interleukin-3-like activity (IL-3-LA) was studied. A significantly lower (-49%, p < 0.005) capacity to synthesize IL-2 and an almost significantly impaired ability (-3...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章


    authors: Bessler H,Karp L,Notti I,Apter A,Tyano S,Djaldetti M,Weizman R

    更新日期:1993-06-01 00:00:00

  • Are Second-Generation Antipsychotics Useful in Tardive Dystonia?

    abstract:OBJECTIVE:To review the current evidence on the effectiveness of second-generation antipsychotics (SGAs) in the treatment of tardive dystonia (TDt) and give recommendations for treatment. METHODS:Medline/PubMed/Psyclit/Embase database searches were conducted in January 2015, and a manual review of references within th...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审


    authors: Pinninti NR,Faden J,Adityanjee A

    更新日期:2015-09-01 00:00:00

  • Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient.

    abstract:OBJECTIVE:Neuroleptic malignant syndrome was induced by aripiprazole in a 12 1/2-year-old boy. The patient had a history of reactive airway disease, pervasive developmental disorder, and learning disability. METHOD:The patient was interviewed and examined, and additional history was taken from the medical records. The...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章


    authors: Palakurthi HB,Parvin MM,Kaplan S

    更新日期:2007-01-01 00:00:00

  • Famotidine adjunctive pharmacotherapy of schizophrenia: a case report.

    abstract::Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporarily related to the open-label addit...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章


    authors: Rosse RB,Kendrick K,Tsui LC,Fay-McCarthy M,Collins JP Jr,Rosenberg P,Wyatt RJ,Deutsch SI

    更新日期:1995-08-01 00:00:00

  • Acute spinal cord injury, part I: pathophysiologic mechanisms.

    abstract::Spinal cord injury (SCI) is a devastating and common neurologic disorder that has profound influences on modern society from physical, psychosocial, and socioeconomic perspectives. Accordingly, the present decade has been labeled the Decade of the Spine to emphasize the importance of SCI and other spinal disorders. Sp...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审


    authors: Dumont RJ,Okonkwo DO,Verma S,Hurlbert RJ,Boulos PT,Ellegala DB,Dumont AS

    更新日期:2001-09-01 00:00:00

  • Heart rate variability during antidepressant treatment with venlafaxine and mirtazapine.

    abstract::Heart rate variability (HRV) reflects the cardiac autonomic regulation, and reduced HRV is considered a pathophysiological link between depression and cardiovascular mortality. So far, there is only limited information on the effects of venlafaxine and mirtazapine on HRV.We studied 28 nondepressed controls and 41 mode...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验


    authors: Terhardt J,Lederbogen F,Feuerhack A,Hamann-Weber B,Gilles M,Schilling C,Lecei O,Deuschle M

    更新日期:2013-11-01 00:00:00

  • Adjunctive use of methylphenidate in the treatment of psychotic unipolar depression.

    abstract::Adjunctive use of methylphenidate, a central stimulant, has been considered as a potential therapeutic choice for patients with refractory unipolar depression, geriatric depression, bipolar depression, and depression secondary to a medical illness. We present a case of psychotic unipolar depression in which the patien...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章


    authors: Huang CC,Shiah IS,Chen HK,Mao WC,Yeh YW

    更新日期:2008-07-01 00:00:00

  • Bupropion Hydrochloride Sustained Release and Diurnal Enuresis: A Previously Unreported Adverse Effect.

    abstract::Bupropion hydrochloride (HCl) is an antidepressant that has many different biological targets, acting as both a norepinephrine-dopamine reuptake inhibitor as well as a nicotinic antagonist. This second-generation antidepressant is available in 3 bioequivalent formulations: immediate release, sustained release, and ext...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章


    authors: Schwitalla TA,Patel RA,Catalano G,Nirmalani-Gandhy A

    更新日期:2019-11-01 00:00:00

  • Clinical usefulness of apomorphine in movement disorders.

    abstract::Apomorphine, the first dopamine agonist to be synthesized, has received a renewed interest in the last few years. This compound acts powerfully on D1 and D2 dopamine receptors and has the most complete pharmacological profile of all clinically available dopamine agonists. When given subcutaneously, apomorphine consist...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审


    authors: Colosimo C,Merello M,Albanese A

    更新日期:1994-06-01 00:00:00

  • Hypothermia induced by atypical neuroleptics.

    abstract::Hypothermia is a potentially life-threatening emergency. This article examines the case of a 34-year-old, mentally retarded man who experienced three episodes of hypothermia during recurrent exposure to pipamperone. After the pipamperone dose was largely reduced, no further hypothermic episodes occurred. Nine other ca...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审


    authors: Schwaninger M,Weisbrod M,Schwab S,Schröder M,Hacke W

    更新日期:1998-11-01 00:00:00

  • Effects of carbamazepine on prolactin secretion in normal subjects and in epileptic subjects.

    abstract::The effects of carbamazepine (CBZ) on spontaneous secretion of prolactin (PRL) and after stimulation with thyrotropin releasing hormone (TRH) were evaluated. Volunteer subjects after acute CBZ administration, and epileptic subjects with complex partial seizures chronically treated with CBZ, were examined. In an epilep...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章


    authors: Bonuccelli U,Murialdo G,Martino E,Lecchini S,Bonura ML,Bambini G,Murri L

    更新日期:1985-01-01 00:00:00

  • Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine.

    abstract::Patients with Parkinson's disease (PD) can experience cognitive impairment. There are currently no medications indicated for the treatment of cognitive impairment in PD. Clinicians are faced with the dilemma as to whether or not to treat patients with PD with the acetylcholinesterase inhibitors that are currently appr...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章


    authors: Richard IH,Justus AW,Greig NH,Marshall F,Kurlan R

    更新日期:2002-11-01 00:00:00

  • The relation between visual hallucinations and visual evoked potential in Parkinson disease.

    abstract:OBJECTIVE:The pathophysiology of hallucinations in Parkinson disease is poorly understood. This study investigated the relation between visual hallucination and visual evoked potentials (VEPs) in Parkinson disease. METHODS:Nineteen patients with Parkinson disease were studied. The authors divided patients into 2 group...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章


    authors: Matsui H,Udaka F,Tamura A,Oda M,Kubori T,Nishinaka K,Kameyama M

    更新日期:2005-03-01 00:00:00

  • Obesity, genetics, and ponderal set point.

    abstract::A significant proportion of the interindividual variance in human fatness is attributable to genetic factors. This fact is indicated (inter alia) by studies of identical twins demonstrating that the degree of efficiency with which the body uses excess dietary energy for fat storage is, to a considerable extent, inheri...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审


    authors: Van Itallie TB

    更新日期:1988-01-01 00:00:00

  • Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.

    abstract::Male albino rats received a stereotaxic injection of 6-hydroxydopamine (6-OHDA) into the right substantia nigra. Animals demonstrating contralateral rotations 2 weeks postoperatively with apomorphine (0.5 mg/kg i.p.) were treated with L-Dopa (55 mg/kg i.p.), bromocriptine (2 mg/kg i.p.), or polyethylene glycol (vehicl...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章


    authors: Schneider MB,Murrin LC,Pfeiffer RF,Deupree JD

    更新日期:1984-01-01 00:00:00

  • Gabapentin treatment for muscle cramps: an open-label trial.

    abstract::To evaluate the efficacy and safety of gabapentin in the treatment of muscle cramps, we engaged an open-label trial with a group of 30 patients with frequent (> 5 cramps/week), stable, long-lasting cramps, associated with different diseases. Gabapentin was effective in reducing the frequency and severity of muscle cra...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章


    authors: Serrao M,Rossi P,Cardinali P,Valente G,Parisi L,Pierelli F

    更新日期:2000-01-01 00:00:00

  • Rare neurodevelopmental abnormalities of sarcosinemia may involve glycinergic stimulation of a primed N-methyl-d-aspartate receptor.

    abstract::Sarcosinemia is a relatively rare autosomal recessive disorder that has a varied phenotypic presentation; rarely, it is associated with neurodevelopmental and neurological abnormalities. Sarcosine is a key intermediate in 1-carbon metabolism, and its elevation in blood and urine could reflect a deficient pool size of ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审


    authors: Deutsch SI,Rosse RB,Long KD,Gaskins B,Mastropaolo J

    更新日期:2006-11-01 00:00:00

  • An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perphenazine.

    abstract:BACKGROUND:BL-1020, a novel gamma aminobutyric acid (GABA) ester of perphenazine, is a new oral antipsychotic with a strong affinity for dopamine and serotonin receptors. Unlike first- and second-generation antipsychotics, it has agonist activity at GABA(A). OBJECTIVE:This is the first study to examine tolerability an...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,多中心研究


    authors: Anand R,Geffen Y,Vasile D,Dan I

    更新日期:2010-11-01 00:00:00

  • Early addition of selegiline to L-Dopa treatment is beneficial for patients with Parkinson disease.

    abstract:OBJECTIVES:To evaluate the clinical outcome of Parkinson disease (PD) patients treated with selegiline (with L-Dopa/decarboxylase inhibitor) in the early stage of the disease in comparison with that of late-stage use of selegiline. METHODS:The study and the reference groups were extracted from a large database of the ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章


    authors: Mizuno Y,Kondo T,Kuno S,Nomoto M,Yanagisawa N

    更新日期:2010-01-01 00:00:00